Key facts
- iSiP’s last known valuation is $15.5M (May 2025).
- It has raised $6.1M; the latest was Early Stage VC ($4.5M) in May 2025.
- Notable investors include DNX Ventures, Deepcore, D3 (Tokyo).
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for iSiP
- ·The full record, as it builds
Funding rounds
No funding rounds for iSiP are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About iSiP
Developer of artificial intelligence drug discovery technology intended for pharmaceutical research and development purposes. The company's platform integrates high-performance computing, physical simulation, and machine learning to generate novel small molecule hit compounds without the need for extensive training data or existing compound information, enabling the global healthcare sector to accelerate the identification of high-value drug candidates with greater efficiency and reduced costs.
- Sector
- Healthcare
- HQ
- Tokyo, Japan
- Founded
- 2022
- Website
- corp-isip.com/
- Ownership
- Privately Held (backing)
iSiP doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in iSiP shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on iSiP in its N-PORT filings yet. We sweep new filings monthly.